Zobrazeno 1 - 10
of 16
pro vyhledávání: '"59"'
Publikováno v:
Transplantation. 78(8)
Background. Studies have provided conflicting results as to the protective role of calcium channel blockers (CCB) in cyclosporine-treated patients with regard to blood pressure control and preservation of renal graft function. Lacidipine is a dihydro
Autor:
Naoko Kamo, Shintaro Yagi, Yusuke Okamura, Toshimi Kaido, Noriyo Yamashiki, Eri Ogawa, Shinji Uemoto, Toshiya Sato, Koichiro Hata, Atsushi Yoshizawa, Hideaki Okajima
Publikováno v:
Transplantation. 102(3)
Early allograft dysfunction (EAD) defined by serum total bilirubin (TB) of 10 mg/dL or greater or prothrombin time-international normalized ratio (PT-INR) of 1.6 or greater on postoperative day 7 (POD 7) or aminotransferase greater than 2000 IU/L wit
Autor:
Denyse Breault, J Nogueira, Debora A. Evans, Stephen C. Jacobs, Matthew R. Weir, Stephen T. Bartlett, David K. Klassen, Mark E. Cooper
Publikováno v:
Transplantation. 90:993-999
Little is known about the long-term outcomes of obese living kidney donors (OLKDs). We undertook this study to describe renal outcomes of OLKDs several years after donation.We invited 101 OLKDs for follow-up health evaluation.Thirty-six subjects (35.
Autor:
Ramasamy Bakthavatsalam, Connie L. Davis, Jorge D. Reyes, Jeffrey B. Halldorson, Nicolae Leca, Paolo R. Salvalaggio, Elizabeth A. Kendrick, Raimund Pichler
Publikováno v:
Transplantation. 89:208-214
BACKGROUND Pediatric en-bloc kidney transplantation into adult recipients is an accepted technique to expand the donor pool. Concerns about adequate "nephron dosing" have traditionally favored placing these kidneys into smaller recipients. METHODS We
Publikováno v:
Transplantation. 83:570-576
BACKGROUND Mycophenolate mofetil (MMF) provides superior prophylaxis against acute rejection when compared with azathioprine (AZA) in heart and renal transplantation. However, it remains unclear whether this results in improved survival or reduced mo
Autor:
Shahid M. Khan, Joshua N. Daniel, Billie Fyfe, Nedjema Sustento-Riodeca, Michael J. Moritz, M. S. A. Kumar, Muhammad I. Saeed, Aparna Kumar, Michael Heifets
Publikováno v:
Transplantation. 81:832-839
Background. Chronic steroid therapy in spite of myriad side effects is widely used in kidney transplantation. This prospective controlled study evaluated safety and efficacy of steroid withdrawal at 2 days in kidney recipients monitored by surveillan
Autor:
Kenneth Yanek, Robert A. Fisher, Daniel G. Maluf, Valeria R. Mas, Kellie J. Archer, Andrea Ferreira-Gonzalez, Anne King, Marc P. Posner
Publikováno v:
Transplantation. 80:1705-1711
BACKGROUND Hypercholesterolemia (HCHL) and hypertriglyceridemia (HTRG) have emerged as the most significant metabolic consequences of therapy with sirolimus. Lipid status can be exacerbated by a variety of factors in the posttransplant setting, inclu
Autor:
Josef Kovarik, Reinhard Kramar, M. Bodingbauer, Veronika Fabrizii, Walter H. Hörl, Wolfgang C. Winkelmayer
Publikováno v:
Transplantation. 80:582-589
BACKGROUND The Eurotransplant Senior Program (ESP) was launched in 1999, targeted to increase the supply of donor kidneys to the elderly. This program requires local allocation of kidneys from cadaveric donors >>65 years to recipients >>65 years. MET
Publikováno v:
Transplantation. 77:1692-1698
Background. The human cytomegalovirus (CMV) is a major cause of morbidity and mortality in transplant patients. In this study, we compared the diagnostic value of pp65 antigen test, qualitative nested polymerase chain reaction (PCR), and quantitative
Autor:
John H. Gordon, D A Laskow, John F. Neylan, Richard B. Freeman, Flavio Vincenti, J. Richard Thistlethwaite, E. Steve Woodle, Robert Mendez, Saleh Aswad, James F. Burdick, Frank L. Delmonico, Alan H. Wilkinson, Russell H. Wiesner, Beth Schwartz, Stephen R. Munn, Lewis Burrows, Gabriel M. Danovitch, David Williamson Shaffer, Hans W. Sollinger, John D. Pirsch, Richard J. Rohrer, Mark H. Deierhoi, Mary Ann Simpson, J. Whelchel
Publikováno v:
ResearcherID
A multicenter trial was conducted to evaluate the efficacy and safety of tacrolimus in the treatment of refractory renal allograft rejection. Renal transplant recipients experiencing biopsy-proven recurrent acute allograft rejection were eligible if